Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Boehringer-Ingelheim"

69 News Found

Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
Drug Approval | June 19, 2024

Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules

Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients


AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis
News | June 01, 2024

AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis

Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine


Lupin, Cost Plus Drug and COPD Foundation to expand access to medication for COPD patients
Healthcare | September 07, 2023

Lupin, Cost Plus Drug and COPD Foundation to expand access to medication for COPD patients

This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US


Bill and Melinda Gates Foundation, UK Govt., Boehringer and GALVmed collaborate to combat African animal trypanosomiasis
News | September 06, 2023

Bill and Melinda Gates Foundation, UK Govt., Boehringer and GALVmed collaborate to combat African animal trypanosomiasis

AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year


Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US
News | August 17, 2023

Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US

Lupin actively contributes to alleviating the burden of COPD for patients across the nation


Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler
Drug Approval | June 22, 2023

Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler

This product will be manufactured at Lupin's Pithampur facility in India


Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
News | April 28, 2023

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.


US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease
News | January 23, 2023

US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease

The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial


US Federal Court dismisses cancer linkage associated with Zantac
News | December 13, 2022

US Federal Court dismisses cancer linkage associated with Zantac

The current ruling will assure the safety of the use of Ranitidine for Indian patients


European Commission approves SPEVIGO for generalized pustular psoriasis flares
Drug Approval | December 13, 2022

European Commission approves SPEVIGO for generalized pustular psoriasis flares

EC grants conditional marketing authorization based on the EFFISAYIL trial